# A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

Source: https://onco.cc/trials/nct06555068/  
OnCo record `nct06555068` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fulvestrant and HRS-8080 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients is a phase 1/2 interventional study registered as NCT06555068 by Jiangsu HengRui Medicine Co., Ltd., with 528 participants planned, started 2024-08-12 and due to reach its primary completion in 2027-12. Interventions recorded: HRS-6209 in Combination with Fulvestrant, HRS-6209 in Combination with HRS-1358, HRS-6209 in Combination with Letrozole, HRS-6209 in Combination with HRS-8080, HRS-6209 in Combination with HRS-9813 and Letrozole and HRS-6209 in Combination with HRS-9813 and HRS-8080.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06555068
- Phase: 1/2
- Setting: An Open-Label, Multi-Center Phase Ib/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Patients With Advanced Unresectable or Metastatic Breast Cancer
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 528

## Sources

- ClinicalTrials.gov NCT06555068: https://clinicaltrials.gov/study/NCT06555068

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [HRS-8080](https://onco.cc/drugs/hrs-8080/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06555068.json